Patent Number: 8,580,743

Title: Modified galectin 9 proteins and methods of treatment using them

Abstract: A recombinant galectin 9 (rGal 9) is provided which exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response.

Inventors: Nishi; Nozomu (Kagawa, JP), Hirashima; Mitsuomi (Kagawa, JP), Yamauchi; Akira (Kagawa, JP), Ito; Aiko (Kagawa, JP)

Assignee: Galpharma Co., Ltd.

International Classification: A61K 38/00 (20060101); C07K 14/00 (20060101); A61K 35/02 (20060101); A61K 35/04 (20060101); C12P 21/00 (20060101)

Expiration Date: 2022-11-12 0:00:00